Dr. Waun Ki Hong, head of M.D. Anderson's Division of Cancer Medicine joins Agennix's Scientific Advisory Board

Houston, TX -- May 14, 2001 -- Agennix Incorporated, a developer of protein and peptide-based drugs targeting oncology, infectious disease and dermatology, today announced that world-renowned medical oncologist Dr. Waun Ki Hong, head of M.D. Anderson's Division of Cancer Medicine, has joined its Scientific Advisory Board.

For the past 17 years, Dr. Hong has held positions at the University of Texas M.D. Anderson Cancer Center, including Chief, Head, Neck and Thoracic Medical Oncology; Professor of Medicine; the Charles A. LeMaistre Distinguished Chair in Thoracic Oncology; Chairman of the Thoracic/Head and Neck Medical Oncology; and his current role, Head of the Division of Cancer Medicine. Prior to his tenure at M.D. Anderson, he was an Associate Professor at Boston University School of Medicine; and Chief of Medical Oncology at Boston Veterans Affairs Medical Center. Dr. Hong has received numerous honors and awards for outstanding research achievements throughout the years. This past March he was named President of the American Association for Cancer Research (AACR) for 2001-2002. In 2000 he was named the winner of the American Society of Clinical Oncology's (ASCO) David A. Karnofsky Award; the AACR Joseph H. Burchenal Award; and the M.D. Anderson Cancer Center Health Memorial award. In addition Dr. Hong sits on the Subspecialty Board of Medical Oncology for the American Board of Internal Medicine; The Board of Scientific Advisors for the National Cancer Institute; and on the Scientific Advisory Board for the Kimmel Foundation on Cancer Research.

"We are honored to have Dr. Hong on our Scientific Advisory Board. His breadth and depth of experience in cancer research and treatment significantly enhances Agennix's development capabilities in the oncology area," said Rick Barsky, CEO of Agennix. "He will be a tremendous asset to us as we bring our products through clinical development."

Agennix is a privately-owned biopharmaceutical company focused on research and development of recombinant human lactoferrin (rhLF), a natural and safe anti-infective and anti-inflammatory protein, and a variety of related peptides. Holding 40 issued patents and 84 pending patents, the Company is engaged in programs that address large market opportunities and unmet medical needs in the areas of oncology, infectious disease and dermatology. Agennix has completed numerous pre-clinical and clinical trials with rhLF demonstrating the enormous potential of lactoferrin in a wide range of clinical conditions. More information about Agennix is available on the Company's web site at: www.agennix.com.